A Phase II trial of gemcitabine for metastatic neuroendocrine tumors
Matthew H. Kulke(Moffitt Cancer Center), Charles S. Fuchs(University of Southern California), Michele Vincitore(Dana-Farber Cancer Institute), Ann Michelini(Dana-Farber Cancer Institute), Jeffrey A. Morgan(Sheba Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Thomas J. Lynch(Nationwide Children's Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Haesook Kim(Dana-Farber Cancer Institute)
Cited by 76
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k